海昆肾喜胶囊联合舒洛地特治疗老年早期糖尿病肾病  

Clinical observation of Haikun Shenxi Capsule combined with sulodexide on treatment of elderly patients with early diabetic nephropathy

作　　者：李敬[1] 焦素敏[2] 王倩 樊星[1] 田领 李晨晨 高燕[1] LI Jing;JIAO Suming;WANG Qian;FAN Xing;TIAN Ling;LI Chenchen;GAO Yan(The Second Department of Nephrology, The Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China;Department of Nephrology, The Second Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China)

机构地区：[1]河北大学附属医院肾内2科,河北保定071000 [2]河北医科大学第二医院肾内科,河北保定050000

出　　处：《西部医学》2020年第7期1058-1061,1066,共5页Medical Journal of West China

基　　金：国家自然科学基金(81500539)。

摘　　要：目的探讨海昆肾喜胶囊联合舒洛地特治疗早期糖尿病肾病老年患者的临床疗效,为其临床应用提供参考依据。方法选择2018年1月~2019年3月河北大学附属医院肾内2科81例诊断为早期糖尿病肾病的老年患者作为观察对象,所有患者均明确为糖尿病肾病Ⅲ期,采用随机数字法平均分为3组:海昆肾喜组27例(单独给予海昆肾喜胶囊治疗)、舒洛地特组27例(单独给予舒洛地特治疗)及联合组27例(海昆肾喜胶囊联合舒洛地特治疗)。治疗8周后,比较3组患者临床疗效、肾功能、肾损伤、细胞因子等相关指标。结果3组患者总有效率比较差异有统计学意义(P<0.05);联合组总有效率高于海昆肾喜组及舒洛地特组(P<0.05)。治疗前及治疗后3组患者BUN及Scr比较差异无统计学意义(P>0.05)。3组患者治疗后24h-UTP、UAER、mAlb、β2-MG及Cys-C均较治疗前有明显降低(P<0.05);治疗后联合组24h-UTP、UAER、mAlb、β2-MG及Cys-C均较海昆肾喜组及舒洛地特组低(P<0.05);治疗后海昆肾喜组24h-UTP、UAER及β2-MG较舒洛地特组更低(P<0.05)。3组患者治疗后VEGF、ACE及IGF-1均较治疗前有明显降低(P<0.05);治疗后联合组VEGF、ACE及IGF-1均较海昆肾喜组及舒洛地特组低(P<0.05);治疗后海昆肾喜组IGF-1较舒洛地特组更低(P<0.05)。结论海昆肾喜胶囊联合舒洛地特治疗早期糖尿病肾病老年患者能有效减少尿蛋白尿,改善肾脏微循环,延缓肾损伤,同时降低细胞因子水平,可在临床推广应用。Objective To explore the clinical efficacy of Haikun Shenxi Capsule combined with sulodexide in the treatment of elderly patients with early diabetic nephropathy,and provide reference for its clinical application.Methods From January 2018 to March 2019,81 elderly patients diagnosed as early diabetic nephropathy in 2 departments of the Affiliated Hospital of Hebei University were selected as the objects of observation.All patients were clearly diagnosed as stage III diabetic nephropathy.They were divided into 3 groups on average by random number method:27 cases in Haikun Shenxi group(treated with Haikun Shenxi capsule alone),27 cases in sulodite group(treated with sulodite alone)and 27 cases in combination group were treated with Haikun Shenxi capsule and sulodette.After 8 weeks of treatment,the clinical efficacy,renal function,renal injury,cytokines and other related indicators of the three groups were compared.Results The difference of total effective rate among the three groups was statistically significant(P<0.05).The total effective rate of combined group was higher than that of Haikun Shenxi group and sulodette group(P<0.05).There was no significant difference in bun and SCR between the three groups before and after treatment(P>0.05).24 hours after treatment,UTP,UAER,mAb,β2 mg and Cys C in the three groups were significantly lower than those before treatment(P<0.05).24 hours after treatment,UTP,UAER,mAb,β2 mg and Cys C in the combined group were lower than those in Haikun Shenxi group and sulodette group(P<0.05).After treatment,24 hours UTP,UAER andβ2 mg in Haikun Shenxi group were lower than those in sulodette group(P<0.05).After treatment,VEGF,ACE and IGF-1 were significantly lower in the three groups than before(P<0.05).After treatment,VEGF,ACE and IGF-1 in the combined group were lower than those in Haikun Shenxi group and sulodette group(P<0.05);IGF-1 in Haikun Shenxi group was lower than that in sulodette group(P<0.05).Conclusion Haikun Shenxi Capsule combined with sulodide has a better clinical eff

关 键 词：海昆肾喜胶囊 舒洛地特 早期 糖尿病肾病 老年 

分 类 号：R587.1[医药卫生—内分泌]